<?xml version='1.0' encoding='utf-8'?>
<document id="20025966"><sentence text="Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam."><entity charOffset="234-243" id="DDI-PubMed.20025966.s1.e0" text="diltiazem" /><entity charOffset="278-287" id="DDI-PubMed.20025966.s1.e1" text="triazolam" /><pair ddi="false" e1="DDI-PubMed.20025966.s1.e0" e2="DDI-PubMed.20025966.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20025966.s1.e0" e2="DDI-PubMed.20025966.s1.e1" /></sentence><sentence text="To predict the magnitude of metabolic drug-drug interaction (mDDI) between triazolam and diltiazem and its primary metabolite N-desmethyldiltiazem (MA)"><entity charOffset="75-84" id="DDI-PubMed.20025966.s2.e0" text="triazolam" /><entity charOffset="126-146" id="DDI-PubMed.20025966.s2.e1" text="N-desmethyldiltiazem" /><pair ddi="false" e1="DDI-PubMed.20025966.s2.e0" e2="DDI-PubMed.20025966.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20025966.s2.e0" e2="DDI-PubMed.20025966.s2.e1" /></sentence><sentence text="" /><sentence text="Relevant in vitro metabolic and inhibitory data were incorporated into a mechanistic physiologically based pharmacokinetic model within Simcyp (Version 9" /><sentence text="1) to simulate the time-course of changes in active CYP3A4 content in gut and liver and plasma concentrations of diltiazem, MA and triazolam in a virtual population with characteristics related to in vivo studies"><entity charOffset="131-140" id="DDI-PubMed.20025966.s5.e0" text="triazolam" /></sentence><sentence text="" /><sentence text="The predicted median increases in AUC(0,infinity) of triazolam, which ranged from 3"><entity charOffset="53-62" id="DDI-PubMed.20025966.s7.e0" text="triazolam" /></sentence><sentence text="9 to 9" /><sentence text="5 for 20 simulated trials (median 5" /><sentence text="9), were within 1" /><sentence text="5-fold of the observed median value (4" /><sentence text="4) in 14 of the trials" /><sentence text=" Considering the effects of diltiazem only and not those of MA, and ignoring auto-inhibition of MA metabolism and inhibition of its metabolism by diltiazem, resulted in lower increases in triazolam exposure (AUC ratios of 1" /><sentence text="5-2" /><sentence text="0 (median 1" /><sentence text="7) and 2" /><sentence text="7-5" /><sentence text="3 (median 3" /><sentence text="4), respectively)" /><sentence text="" /><sentence text="Prediction of mDDIs involving diltiazem requires consideration of both competitive and time-dependent inhibition in gut and liver by both diltiazem and MA, as well as the complex interplay between the two moieties with respect to mutual inhibition of parent compound and its metabolite" /><sentence text="" /></document>